Phase 1 Safety and Immunogenicity of CVnCoV in Healthy Adults

Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CVnCoV with Placebo (2 arms). Primary endpoints: Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination, Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination and 5 more. Started Jun 2020; status: completed.